PriceTargets.com logo

NASDAQ:BLU - BELLUS Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.25
  • Forecasted Upside: 110.49 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$7.72 As of 05/25/2022 01:00 AM ET
▼ -0.35 (-4.34%)

This chart shows the closing price for BLU by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BELLUS Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLU

Analyst Price Target is $16.25
▲ +110.49% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for BELLUS Health in the last 3 months. The average price target is $16.25, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 110.49% upside from the last price of $7.72.

This chart shows the closing price for BLU for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in BELLUS Health. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/24/2022HC WainwrightBoost Price TargetBuy$14.00 ➝ $16.00High
12/13/2021BTIG ResearchBoost Price TargetBuy ➝ Buy$13.00 ➝ $18.00High
12/13/2021Evercore ISIBoost Price TargetOutperform ➝ Outperform$12.00 ➝ $20.00High
12/7/2021Royal Bank of CanadaBoost Price TargetOutperform$9.00 ➝ $11.00High
11/16/2021HC WainwrightReiterated RatingBuy$14.00High
10/18/2021Royal Bank of CanadaBoost Price TargetOutperform$8.00 ➝ $9.00High
10/5/2021BTIG ResearchReiterated RatingBuy$13.00Low
9/26/2021BTIG ResearchReiterated RatingBuy$13.00Medium
9/14/2021BTIG ResearchBoost Price TargetPositive ➝ Buy$9.00 ➝ $13.00High
9/14/2021HC WainwrightReiterated RatingPositive ➝ Buy$10.00 ➝ $14.00High
8/13/2021Bloom BurtonReiterated RatingBuyLow
7/29/2021BTIG ResearchInitiated CoverageBuy$9.00High
5/23/2021Evercore ISIReiterated RatingBuy$12.00High
1/29/2021Royal Bank of CanadaInitiated CoverageOutperform$8.00High
11/18/2020Evercore ISIInitiated CoverageOutperform$12.00High
11/12/2020Lifesci CapitalReiterated RatingOutperformMedium
8/14/2020HC WainwrightLower Price TargetBuy$28.00 ➝ $10.00Medium
8/13/2020Ci CapitalReiterated RatingBuy$7.00Medium
7/7/2020Robert W. BairdLower Price TargetOutperform$14.00 ➝ $6.00High
7/7/2020GuggenheimDowngradeBuy ➝ NeutralHigh
7/6/2020MackieDowngradeBuy ➝ Hold$8.70High
6/26/2020HC WainwrightInitiated CoverageBuy$28.00High
3/5/2020CowenReiterated RatingBuyMedium
9/30/2019JBL AdvisorsInitiated CoverageBuyMedium
9/30/2019CowenInitiated CoverageOutperformHigh
9/30/2019GuggenheimInitiated CoverageBuy$12.00High
9/30/2019Jefferies Financial GroupInitiated CoverageBuy$20.00High
9/6/2019Bloom BurtonReiterated RatingBuyLow
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2021
  • 7 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2022

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
BELLUS Health logo
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
Read More

Today's Range

Now: $7.72
Low: $7.62
High: $8.02

50 Day Range

MA: $7.73
Low: $6.19
High: $8.97

52 Week Range

Now: $7.72
Low: $2.60
High: $9.84

Volume

363,883 shs

Average Volume

948,358 shs

Market Capitalization

$824.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.19

Frequently Asked Questions

What sell-side analysts currently cover shares of BELLUS Health?

The following equities research analysts have issued stock ratings on BELLUS Health in the last twelve months: Bloom Burton, BTIG Research, Evercore ISI, HC Wainwright, Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for BLU.

What is the current price target for BELLUS Health?

0 Wall Street analysts have set twelve-month price targets for BELLUS Health in the last year. Their average twelve-month price target is $16.25, suggesting a possible upside of 110.5%.
View the latest price targets for BLU.

What is the current consensus analyst rating for BELLUS Health?

BELLUS Health currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BLU will outperform the market and that investors should add to their positions of BELLUS Health.
View the latest ratings for BLU.

How do I contact BELLUS Health's investor relations team?

BELLUS Health's physical mailing address is 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7. The company's listed phone number is (450) 680-4500 and its investor relations email address is [email protected] The official website for BELLUS Health is www.bellushealth.com. Learn More about contacing BELLUS Health investor relations.